[Comparison between integrated 24-hour concentrations of growth hormone, insulin-like growth factor I and prolactin in acromegalic patients treated with octreotide and patients treated with octreotide LAR].
The current therapeutic options for acromegalic patients (surgery, radiation therapy and/or pharmacological treatment) do not always lead to a definitive resolution of the disorder. Recently, octreotide (OC) and, more recently, octreotide LAR (OC-LAR), a new slow-release formulation of the long-acting somatostatin analog, have been regarded as the primary treatment for acromegaly. This study reports our observations of the integrated 24-hour concentrations of GH, IGF-I and prolactin (PRL) in acromegalic patients treated with octreotide (OC) and octreotide LAR (OC-LAR), highlighting lower percentages of apparent remissions.